10-Q: PetMed Express Q1 Loss Deepens Amid Impairment, Sales Decline

PetMed Express reports a significant net loss of $34.15 million for Q1 2026, driven by a $27.26 million goodwill and intangible asset impairment and a 22.7% drop in net sales.

Summary

• A net loss of $34.152 million was reported for the three months ended June 30, 2025 (Q1 fiscal year 2026), a significant decline from a net income of $3.754 million in the prior year's restated period.
• Net sales decreased by 22.7% to $51.180 million for the quarter, down from $66.207 million in the same period last year, primarily due to reduced advertising, higher consumer promotional usage, and a decline in prescription medication sales.
• The Company recorded a goodwill impairment charge of $26.7 million and an intangible asset impairment charge of $0.6 million, totaling $27.258 million, reflecting a downward revision to forecasts and a sustained decrease in market capitalization.
• Gross profit decreased by 24.3% to $14.403 million, with the gross margin percentage falling to 28.1% from 28.8% in the prior year, mainly due to lower sales, higher discount activity, and increased freight costs.
• General and administrative expenses increased by 165.7% to $12.948 million, driven by an $8.8 million increase in stock-based compensation expense and a $0.9 million increase in professional fees related to an investigation.
• Advertising expenses decreased by 25.0% to $6.046 million, but the advertising cost of acquiring a new customer increased to $71 from $67, and new customer acquisitions fell to approximately 85,000 from 120,000.
• Cash and cash equivalents decreased by $13.593 million during the quarter, ending at $41.127 million as of June 30, 2025.
• Net cash used in operating activities increased to $12.271 million for the quarter, compared to $8.517 million in the prior year.
• The Company's unaudited consolidated financial statements for the quarter ended June 30, 2024, were restated to correct material errors in accounting for vendor-funded programs.
• In December 2025, the Company received public unsolicited and non-binding acquisition proposals ranging from $4 to $4.25 per share in cash.

Sentiment

Score: 2

Explanation: The company reported a substantial net loss driven by significant impairment charges and a sharp decline in sales. Operational metrics like new customer acquisition and gross margin also deteriorated. While there are unsolicited acquisition proposals, the underlying business performance is very weak, and internal control weaknesses persist.

Positives

• Recurring net sales as a percentage of total gross sales increased to 57.7% for the quarter ended June 30, 2025, up from 52.6% in the prior year, indicating improved customer retention or subscription model adoption.
• The Board is reviewing unsolicited acquisition proposals, which could potentially offer a premium to shareholders.
• The Company successfully opposed the Plaintiff's motion to remand the class action case back to the Court of Common Pleas, keeping it in federal court.

Negatives

• A significant net loss of $34.152 million was reported for the quarter, a substantial deterioration from the prior year's net income.
• Net sales decreased by 22.7% to $51.180 million, indicating a significant decline in revenue.
• Goodwill and intangible asset impairment charges totaling $27.258 million were recorded, reflecting a substantial write-down of asset values due to reduced forecasts and market capitalization.
• Gross profit decreased by 24.3% and gross margin declined to 28.1% due to lower sales, higher discount activity, and increased freight costs.
• General and administrative expenses surged by 165.7% due to increased stock-based compensation expense and professional fees related to an investigation.
• New customer acquisition decreased to approximately 85,000 from 120,000, and the cost per acquisition increased to $71 from $67, indicating less efficient marketing spend.
• Cash and cash equivalents declined by $13.593 million during the quarter.
• Net cash used in operating activities increased to $12.271 million from $8.517 million in the prior year.
• Prior period financial statements for Q1 2024 were restated due to material accounting errors related to vendor-funded programs.
• Disclosure controls and procedures were not effective as of June 30, 2025, due to identified material weaknesses in internal control over financial reporting.
• The quarterly dividend was suspended indefinitely as of October 26, 2023.

Risks

• Macroeconomic factors, including inflation, increased interest rates, significant capital market and supply chain volatility, and geopolitical developments, are expected to continue impacting operations and consumer spending patterns for the remainder of fiscal 2026.
• Increased competition and consumers giving more consideration to price may adversely affect future sales.
• The ultimate outcome of legal proceedings, including a class action lawsuit alleging deceptive pricing practices and potential actions from state pharmacy boards, is uncertain and could have a negative impact on results.
• There is no assurance that the Company will be successful in protecting its trade or service marks.
• Unsolicited acquisition proposals and attempts to acquire control of the Company could cause significant expense, disrupt business, and impact the stock price.
• Material weaknesses in internal control over financial reporting could lead to financial misstatements and impact investor confidence.
• Future sales growth is not guaranteed, and changes in consumer behavior due to macroeconomic factors make future sales challenging to predict.
• Interest income may decrease in the future based on utilization of cash balances on future investments or operating activities, or if the current interest rate environment changes.

Future Outlook

The Company expects macroeconomic factors, including inflation, increased interest rates, and supply chain volatility, to continue impacting operations and consumer spending patterns for the remainder of fiscal 2026. Future sales growth is not guaranteed, and the Company anticipates challenges in predicting consumer behavior. Management is evaluating unsolicited acquisition proposals to determine the best course of action for shareholders.

Management Comments

• We believe that our cash and cash equivalents currently on hand and expected cash flows from future operations will be sufficient to continue operations for at least the next twelve months.
• We proactively seek opportunities to improve the efficiency of our operations, take steps to realize internal cost savings, including aligning our staffing needs, creating a more variable cost structure to better support our current and expected future levels of operations and process streamlining.
• The Board of Directors reviews and discusses the capital allocation needs of the Company on a quarterly basis, and as part of that review, on October 26, 2023, our Board of Directors elected to suspend the quarterly dividend indefinitely. This action was intended to focus use of the Company’s existing cash and cash flow on growth initiatives and other, higher return initiatives.
• The Company’s Board, consistent with its fiduciary duties and in consultation with its financial and legal advisors, will carefully review and consider the acquisition proposals to determine the course of action that it believes is in the best interests of the Company and its stockholders.

Industry Context

The pet care industry, particularly online pharmacies, faces increasing competition and evolving consumer behavior influenced by macroeconomic factors such as inflation and rising interest rates. PetMed Express's decline in sales and new customer acquisition, alongside increased customer acquisition costs, suggests challenges in maintaining market share and profitability in a competitive and economically uncertain environment. The increase in recurring net sales percentage could indicate a shift towards subscription models, aligning with broader industry trends for stable revenue streams, but overall performance lags.

Management Changes

Corporate Governance

Legal Proceedings

• A class action lawsuit was filed by Timothy Fitchett on April 18, 2024, alleging violation of Pennsylvania's Unfair Trade Practices and Consumer Protection Law regarding 'reg. prices' for products. The Company denies liability and intends to defend the action.
• The Company may from time to time be involved in various other claims and lawsuits in the ordinary course of business, including claims related to products, product warranties, contracts, employment, intellectual property, consumer protection, pharmacy, and other regulatory matters.
• Past settlements with various state pharmacy boards have occurred, with no assurances that other states will not attempt similar actions in the future.
• The Company intends to vigorously defend its trade or service marks, but there can be no assurance of success.

Stakeholder Impact

• Shareholders: Negative impact due to significant net loss, impairment charges, and declining sales. Potential positive impact from unsolicited acquisition proposals if a favorable deal is struck. The indefinite suspension of dividends impacts income-focused shareholders. The Shareholder Rights Plan aims to protect long-term value.
• Employees: Management changes (CEO, CFO) indicate potential instability. Severance packages were provided to departing executives.
• Customers: Higher consumer promotional usage suggests price sensitivity. The decline in prescription medication sales and new customer acquisition indicates potential loss of market share or reduced demand.
• Suppliers: The decline in sales and higher discount activity could potentially impact supplier relationships or terms.
• Creditors: Deteriorating financial performance and cash position could raise concerns, although no debt obligations are mentioned.

Next Steps

• Management will continue to monitor, evaluate, and manage operating plans, forecasts, and liquidity in light of macroeconomic conditions.
• The Board will carefully review and consider the unsolicited acquisition proposals to determine the best course of action for shareholders.
• The Company is evaluating the impact of adopting new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06).
• Remediation of material weaknesses in internal control over financial reporting is ongoing.

Key Dates

Recommendation

The company's Q1 2026 results are exceptionally poor, marked by a substantial net loss, significant impairment charges, and a sharp decline in sales across all categories. The increase in general and administrative expenses, coupled with higher customer acquisition costs despite reduced advertising spend, points to fundamental operational inefficiencies and a deteriorating business model. The material weaknesses in internal controls and the restatement of prior financials further erode confidence. While unsolicited acquisition proposals offer a potential exit, the current operational trajectory is highly concerning, warranting a strong sell recommendation for investors focused on underlying business performance.

Keywords

PetMed Express, PETS, 10-Q, Q1 2026, financial results, net loss, sales decline, goodwill impairment, intangible asset impairment, pet pharmacy, online pet supplies, e-commerce, veterinary services, corporate governance, management changes, acquisition proposals, financial restatement, internal controls, shareholder rights plan